SEC Filing Summary: Creative Medical Technology Holdings, Inc. (CELZ)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Creative Medical Technology Holdings, Inc. on March 14, 2025, covering events occurring on March 10, 2025. The Company is incorporated in Nevada and its common stock trades on The Nasdaq Stock Market LLC under the symbol "CELZ."
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific executive compensation payments approved by the Compensation Committee.
Material Changes
The primary material event reported is the approval of discretionary bonuses for senior executive officers:
- Timothy Warbington (Chief Executive Officer): Approved bonus of $70,000.
- Donald Dickerson (Chief Financial Officer): Approved bonus of $30,000.
Total compensation approved in this event: $100,000.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items beyond the executive compensation approval. No new risks or operational changes were disclosed in this report.
Investor Verification Checklist
- Verify the source of funds for the $100,000 in executive bonuses and whether this impacts current liquidity.
- Review the Company's most recent 10-K or 10-Q filings for baseline financial performance, as this 8-K does not contain operational metrics.
- Confirm if these bonuses are tied to specific performance milestones or are discretionary, as the filing does not specify the criteria.